Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 48
Traveling to UK with Peptides: The Rules
UK law sets clear documentation rules for controlled drugs like TRT, while CJC-1295 and ipamorelin sit in a separate, less defined space.
GLP-1 agonists: laryngeal side effects
A 2026 study found GLP-1 receptor agonists raised cough and voice disorder risk in obese adults.
Beyond weight loss: GLP-1 organ outcomes
A JACC editorial reframes GLP-1 drugs as cardiometabolic medicines. The SELECT, FLOW and SOUL trials, and the approved labels, already point that way.
Do GLP-1 drugs cause throat symptoms?
A 2026 Laryngoscope cohort ties GLP-1 drugs to cough, globus and voice change. Here is what an association study can and cannot show.
GLP-1 drugs as cardiometabolic medicines
A 2026 JACC editorial argues GLP-1 drugs are cardiometabolic medicines first. Here is what the trial evidence shows.
What Lilly's retatrutide lawsuits mean
Eli Lilly sued six US sellers of unapproved retatrutide on 12 August 2026. Here is what the cases mean if you bought a vial or are considering one.
Obesity-driven HFpEF: what the drugs do
A 2026 review maps obesity-driven HFpEF from mechanism to prescribing. Semaglutide and tirzepatide improved symptoms and exercise capacity, not survival.
Semaglutide and depression: 2026 review
A 2026 meta-analysis found no significant depression risk from semaglutide, but high heterogeneity and real-world signals leave the picture unsettled.
BPC-157 and TB-500 after shoulder surgery
Animal studies link BPC-157 and TB-500 to tendon healing, but controlled human evidence for orthopaedic surgery is essentially absent.
Semaglutide and body anxiety explained
Semaglutide users often report new health anxieties about muscle loss and nutrition. Here is what the research actually shows and what remains unknown.
Semaglutide bloating and nausea: trial data
Nausea, bloating and diarrhoea top the side-effect list for semaglutide. Here is what the STEP trial data says about how common they are and why.
What semaglutide does to daily life in MASH
A new ESSENCE analysis puts a number on how people with MASH feel on semaglutide: a small EQ-5D utility gain, and why payers will care about it.